# A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

> **NCT03673501** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 453 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Ripretinib
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT03673501
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-02-08
- **Primary completion:** 2021-09-01
- **Final completion:** 2026-12
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03673501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03673501, "A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03673501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*